What it sells
AI regulatory compliance.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHeads of safety/pharmacovigilance, regulatory, clinical and AI/digital innovation at regulated enterprises.
Trigger: what makes them buy now?
AI initiatives stall at regulatory (GxP) requirements; fragmented safety, regulatory and clinical systems.
Workflow: what inputs become what output?
Converts regulations/SOPs into machine-readable compliance logic, orchestrates AI workflows across systems with compliance enforced at each step, and produces continuous audit-ready evidence; use cases: pharmacovigilance case processing, regulatory submissions, clinical development.
Economics: what it saves and how it charges
Claims faster validation/submission timelines, lower cost via automated compliance enforcement, continuous audit readiness; commercial model not stated.
Distribution: how it reaches customers
Demo-led enterprise sales ("Book a Demo"); recently announced seed round.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-04-23 | — | $8.6M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.